ClinicalTrials.Veeva

Menu

Prospective Database for Prediction of Atrial Fibrillation in Pacemaker and ICD Patients (SAFE-ME)

M

Medical University of Graz

Status

Enrolling

Conditions

Atrial Fibrillation
Pacemaker Ddd
ICD

Treatments

Diagnostic Test: 24 hour Holter ECG Monitoring

Study type

Observational

Funder types

Other

Identifiers

NCT03357926
29-229 ex 16/17

Details and patient eligibility

About

Atrial fibrillation (AF) is associated with a five-fold increased risk of cerebrovascular stroke. While the risk of stroke in patients with known AF can be calculated via AF stroke prediction risk scores, the prediction of AF occurrence per se in individual patients remains difficult.

We will recruit 250 patients with an implanted dual-chamber Pacemaker (PM) or an implantable cardioverter Defibrillator (ICD) with atrial lead to ensure continuous rhythm monitoring during follow up. At baseline, we will gather clinical and device data of patients. For AF prediction based on surface Electrocardiography (ECG), 24-h Holter ECG monitoring will be performed. After 6 months, we will assess the occurrence of AF during the study period via interrogation of PM/ICD. The resulting data will be used to develop algorithms including clinical, device and ECG data for prediction of the development of AF in individual patients. If possible, we will develop a risk score of high accuracy by combination of demographical, clinical and technical parameters of device patients. The resulting risk score could potentially help to facilitate the decision if anticoagulation is necessary in patients with either risk of AF or embolic stroke of unknown origin. Furthermore, Hayn et al. (AIT Austrian Institute of Technology) are currently developing algorithms to predict the occurrence of AF surface ECG data. It is an additional aim of this project to support the development of this algorithm in pacemaker and ICD patients and to increase the accuracy of AF prediction with clinical parameters and other parameters available to patients with implanted pacemaker (PM) or implanted cardioverter-defibrillator (ICD).

Enrollment

250 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Implanted pacemaker or implanted cardioverter defibrillator (ICD) with atrial lead
  • CHADS-VASc Score of 2 or more
  • Sinus rhythm or atrial paced rhythm
  • Atrial stimulation rate 50% or less
  • ModeSwitch rate 50% or less since last pacemaker interrogation

Exclusion criteria

  • pacemaker or ICD malfunction
  • atrial fibrillation (AF) at time of pacemaker / ICD interrogation
  • AF during 24-hour Holter ECG monitoring
  • permanent AF

Trial design

250 participants in 1 patient group

Observation Group
Treatment:
Diagnostic Test: 24 hour Holter ECG Monitoring

Trial contacts and locations

1

Loading...

Central trial contact

Daniel Scherr, Assoc.Prof. PD Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems